ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2023
Dose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study.
Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 13 citations in OpenAlex.
- Assessment of planning organ at risk volume margins in non-adaptive pancreatic stereotactic body radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Dosimetric Challenges of Small Lung Lesions in Low-Density Tissue Treated with Stereotactic Body Radiation Therapy.Journal of clinical medicine · 2026Article
- Classification performances of two diode arrays for patient-specific quality assurance of stereotactic body radiation therapy treatments based on absolute dose measurements in phantom.Journal of applied clinical medical physics · 2025Article
- A Japanese national survey on IMRT/SBRT in 2023 by the JASTRO High-Precision External Beam Radiotherapy Group.Journal of radiation research · 2025Article
- Uncertainties in outcome modelling in radiation oncology.Physics and imaging in radiation oncology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 1 country.
Funding
Abstract
background and purposeRadiation dose prescriptions are foundational for optimizing treatment efficacy and limiting treatment-related toxicity. We sought to assess the lack of standardization of SBRT dose prescriptions across institutions. MATERIALS &
methodsDosimetric data from 1298 patients from 9 academic institutions treated with IMRT and VMAT were collected. Dose parameters D
resultsDisease sites included lung (48.3 %) followed by liver (29.7 %), prostate (7.5 %), spine (6.8 %), brain (4.1 %), and pancreas (2.5 %). The PTV volume in lung varied widely with bimodality into two main groups (22.0-28.7 cm
conclusionsThe SBRT prescriptions in the literature or in treatment guidelines currently lack nuance and hence there is significant variation in dose prescriptions across academic institutions. These findings add greater importance to the identification of dose parameters associated with improved clinical outcome comparisons as we move towards more hypofractionated treatments. There is a need for standardized reporting to help institutions in adapting treatment protocols based on the outcome of clinical trials. Dosimetric parameters are subsequently needed for uniformity and thereby standardizing planning guidelines to maximize efficacy, mitigate toxicity, and reduce treatment disparities are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.